BPC-157 + TB-500 (Wolverine Stack) Reconstitution Calculator & Dosing Protocol for Injury Recovery

Two Vials, Two Schedules

BPC-157 and TB-500 use different dose scales and schedules: BPC-157 runs daily in micrograms, while TB-500 runs twice weekly in milligrams. Separate vials preserve those schedules. A premixed vial is simpler to handle but fixes the ratio and forces both peptides onto one schedule.

The two peptides target different repair bottlenecks. BPC-157 supports new capillary growth and blood supply¹. TB-500 supports the movement of repair cells that organize new tissue². Their pairing is intended to address perfusion and cell migration together.

No human trial has tested the combination. BPC-157 evidence is predominantly preclinical, with one 12-patient clinical study³. Full-length TB-4, the parent protein related to the TB-500 fragment, has preclinical research and Phase 1 human safety data⁴. The protocol is practitioner-derived rather than validated in a controlled trial of the pair.

For the mechanism deep-dives, see the standalone guides: BPC-157 and TB-500 / TB-4. For the narrative injury-recovery walkthrough, see the Wolverine Stack guide.

How Wolverine Stack Doses and Reconstitution Are Calculated

Start by identifying whether the peptides are in two individual vials or one combined vial.

• Individual vials — reconstitute each peptide separately and retain its independent schedule.
• Combined blend vial — both peptides premixed in one vial at a fixed ratio. One reconstitution, and every draw delivers both at that ratio. Convenient, but it couples the two schedules into one.

Every case below uses the same formula:

$$V_{\text{draw}}=\frac{D\times V_{\text{water}}}{M}$$

$V_{\text{draw}}$ is the syringe draw (mL), $D$ the target dose, $V_{\text{water}}$ the BAC water added (mL), and $M$ the vial mass of the compound being solved for. Match the units of $D$ and $M$: both mg, or both mcg.

Path 1 — Individual vials (recommended)

Reconstitute each vial separately, then dose on its own schedule.

BPC-157 — 500 mcg daily. The two common vial sizes both land on a 10-unit draw:

$$V_{\text{draw}}=\frac{500\text{ mcg}\times 1\text{ mL}}{5000\text{ mcg}}=0.1\text{ mL}=10\text{ units on a U-100 syringe}$$

• 5 mg vial + 1 mL BAC water → 0.1 mL (10 units) delivers 500 mcg; lasts 10 doses
• 10 mg vial + 2 mL BAC water → 0.1 mL (10 units) delivers 500 mcg; lasts 20 doses
• For a 250 mcg starting dose, halve the draw to 0.05 mL (5 units)

TB-500 — 2.5 mg twice weekly. Both sizes land on a 50-unit draw:

$$V_{\text{draw}}=\frac{2.5\text{ mg}\times 2\text{ mL}}{10\text{ mg}}=0.5\text{ mL}=50\text{ units on a U-100 syringe}$$

• 10 mg vial + 2 mL BAC water → 0.5 mL (50 units) delivers 2.5 mg; lasts 4 doses
• 5 mg vial + 1 mL BAC water → 0.5 mL (50 units) delivers 2.5 mg; lasts 2 doses
• For a 2 mg dose, the same reconstitution gives a 0.4 mL (40-unit) draw

On overlap days, practitioner protocols sometimes co-draw BPC-157 and TB-500 because their solutions are pH compatible. NAD+ requires a separate syringe and site because its acidity can degrade peptides on contact.

Path 2 — Combined blend vial

A blend vial holds both peptides at a fixed mass ratio, so one reconstitution sets both, and every draw delivers them in that ratio. The tradeoff: you pick one schedule for the pair instead of running each on its own.

Standard 1:1 blends — 5/5 and 10/10. Equal mass of each peptide. A "10 mg wolverine stack" is 5 mg BPC-157 + 5 mg TB-500; a "20 mg" is 10 mg + 10 mg.

• 5/5 vial (10 mg total) + 1 mL BAC water → each 0.1 mL (10-unit) draw delivers 0.5 mg BPC-157 and 0.5 mg TB-500
• 10/10 vial (20 mg total) + 2 mL BAC water → same 0.5 mg + 0.5 mg per 0.1 mL draw, with twice the doses per vial

Because the ratio is 1:1, a daily 0.1 mL draw keeps BPC-157 in its usual 500 mcg range but delivers TB-500 every day rather than pulsed twice weekly. That is the blend tradeoff; separate vials (Path 1) avoid it.

Custom (non-1:1) blends — anchor one compound. When the two masses are not equal, pick the compound whose dose you want to fix — the anchor — set its dose, and the other peptide scales by the ratio. This is the same anchor math the KLOW calculator uses.

Example — a 10 mg BPC-157 / 5 mg TB-500 vial (a 2:1 blend), anchored to 500 mcg BPC-157, reconstituted in 2 mL:

$$V_{\text{draw}}=\frac{0.5\text{ mg}\times 2\text{ mL}}{10\text{ mg}}=0.1\text{ mL}=10\text{ units}$$

That same 0.1 mL draw also delivers 250 mcg TB-500 — half the BPC-157 dose, by the 2:1 ratio.

The Calculator above solves either path — individual vials or a blend at any ratio — for any vial size or target dose.

Dosing Protocol

The higher BPC-157 dose is the escalation range. TB-500 doses are spaced at least 72 hours apart; NAD+ is a conditional add-on for chronic, post-surgical, or energy-limited recovery.

Cycle length: 8–12 weeks for BPC-157, 6–10 weeks for TB-500. TB-500 can taper to once weekly after week 6 if the injury is stable.

Cycle structure

BPC-157 stays daily throughout; TB-500 front-loads, then tapers as the tissue starts holding.

Why BPC-157 is daily and TB-500 is not

BPC-157 delivers a signal. A small daily dose triggers repair cascades — new blood vessel formation, nitric oxide production, repair-cell migration¹ — that keep running after the peptide itself clears. Daily dosing keeps that signaling environment switched on.

TB-500 follows a concentration-dependent mechanism rather than a small daily signal². Practitioner protocols therefore use milligram-scale doses twice weekly, front-loading 3–4 mg through weeks 1–4 and tapering as the tissue stabilizes. Doses below that protocol range may not reach the proposed concentration threshold.

Weekly schedule

Specific weekdays matter less than spacing TB-500 doses at least 72 hours apart. On the example schedule, Monday and Thursday are overlap days. NAD+ remains in a separate syringe and site.

Injection routing

Near-injury injection, where easy and safe to reach, is the convention. Neither peptide "stays local" — both enter systemic circulation within minutes — but local injection may give a higher first-pass tissue concentration before that dilution⁵. Safe placement matters more than a perfect site: for hard-to-reach injuries (spine, deep hip), abdomen or thigh works. See Where to Inject Peptides for the full breakdown.

How the Stack Works

Healing stalls when two things fail at once: the blood supply to the injury closes down, and the repair cells that rebuild tissue cannot move into position. The stack assigns one peptide to each problem.

BPC-157: blood supply

BPC-157 is a 15-amino-acid fragment of a protein found in gastric juice. Preclinical research associates it with new capillary growth, nitric oxide signaling, and the FAK-paxillin pathway involved in repair-cell attachment and migration¹,⁶. These mechanisms provide the rationale for its use as the perfusion component of the stack.

TB-500: repair-cell movement

TB-500 is usually the thymosin beta-4 fragment 17–23, the short sequence tied to repair-cell movement. Every cell has internal scaffolding made of actin; TB-500 supports the actin-side signal repair cells use to migrate into damaged tissue (actin-binding repair signal²). Where BPC-157 restores the blood supply, TB-500 helps the right cells reach the right place so tissue can organize rather than scar.

One caution on identity: TB-500 (the fragment) and full-length TB-4 (43 amino acids) are related but not interchangeable, and product labels blur the two routinely⁷. The stronger anti-scarring and tissue-remodeling claims come from full-length TB-4 research, not the isolated fragment. If scar remodeling is the goal, confirm the molecular weight on the certificate of analysis: around 800 Da is the fragment, around 4,900 Da is full-length. See the TB-500 guide for the full distinction.

Why they need each other

In a rat model, combined BPC-157 + TB-4 restored contractile function earlier than either compound alone⁸.

What the Wolverine Stack Is Not For

The stack does one thing: it clears the perfusion-and-migration bottleneck — BPC-157 reopens blood flow, TB-500 moves repair cells along it. It works wherever that coupled bottleneck is what stalled healing: tendon, ligament, muscle, fascia, joint capsule, and scar or connective tissue. Where a different bottleneck governs the tissue, restoring blood flow and cell migration never reaches the thing that is actually stuck.

• Bone / fracture — Healing runs on osteoblast–osteoclast mineralization and callus formation. Neither peptide acts on bone matrix — more blood flow to a fracture does not lay down mineral.
• Isolated cartilage — Cartilage is avascular, so there is no circulation to restore; chondrocyte and matrix biology set the pace, and a systemic SubQ stack cannot reach a focal joint surface. The cartilage-specific lever is cartalax.
• Peripheral nerve — Axonal regrowth runs on Schwann-cell and neurotrophic signaling, not blood supply — nerve does not regrow because you fed it more blood. For nerve repair and small-fiber neuropathy, ARA-290 is the load-bearing compound.
• Central nervous system (stroke, TBI) — These need blood-brain-barrier crossing and CNS-specific signaling; BPC-157 and TB-500 are peripheral repair peptides in the wrong compartment. Semax is the CNS-active option.

One honest caveat: BPC-157 and TB-500 show isolated preclinical signals in spinal-cord-injury models, so the precise statement is that the Wolverine Stack is a peripheral soft-tissue tool — not that the peptides are inert everywhere else. For a real-world protocol, bone, cartilage, nerve, and CNS are out of scope by mechanism.

When to Add NAD+

BPC-157 + TB-500 cover blood supply and cell movement — the layers most injuries need first. NAD+ is the first thing to add when those two are working but progress stalls anyway, because repair cells cannot build collagen or remodel tissue without enough cellular energy.

NAD+ from the start fits any of these: a chronic or 6-month-plus injury, post-surgical recovery, high training load, or recovery that feels systemically draining. 50–250 mg IM, about 3× weekly, in a separate syringe and a separate site — NAD+ is acidic (pH 3–4) and will degrade the peptides if co-injected. It also stings; a slow push and a room-temperature solution help.

NAD+ is not the only possible add, but it is the default first one. The other two layers are conditional:

• GHK-Cu — considered when poor load-bearing quality suggests collagen organization is the remaining bottleneck.
• KPV — fits when inflammation keeps cycling back (swelling returns after moderate activity despite four-plus weeks). It pre-empts the inflammation switch (NF-κB⁹).

For all three layers at once, the Injury Recovery Protocol is the cleaner path than bolting compounds onto this stack one at a time.

Tell FoxAI about your injury and it builds the right protocol→

Phenotype Considerations

• Chronic injuries (6+ months). More than two bottlenecks are likely — established scar tissue and adapted blood-supply patterns on top of the vascular and migration layers this stack addresses. The fit is NAD+ from the start and a full 12-week cycle.
• Post-surgical. The convention defers until the initial clotting window has settled (usually two weeks) unless a clinician directs otherwise. Early angiogenesis can complicate fresh surgical healing.
• On a GLP-1 or in a caloric deficit. Repair runs on energy the deficit is restricting. NAD+ becomes a first-line add rather than a conditional one, and protein intake matters more (see Supporting Factors).
• WADA-tested athletes. TB-500 is prohibited and BPC-157 is WADA S0; the stack is not usable in tested competition. Metabolites of both are detectable.

Supporting Factors

Peptides provide the repair signal. The raw materials come from nutrition and loading.

These inputs supply repair substrates and controlled mechanical loading. Peptide use does not replace physical therapy; new collagen still requires directional load to organize.

When Progress Stalls

The stall pattern is the thing to read, rather than pushing the dose higher.

• Early improvement that levels off. The vascular and migration bottlenecks have cleared and a different one — energy, collagen quality, or inflammation — is now rate-limiting. The matching layer (NAD+, GHK-Cu, or KPV) is what addresses it.
• Tissue warm but energy flagging. Repair has the signal but not the fuel: NAD+ added or tightened, with the protein floor and sleep checked first.
• Nothing by week 3. Usually a materials or technique problem before it is a dose problem — the certificate of analysis, injection technique, and storage (refrigerated, protected from light) are the checks, since peptide degradation is the most common cause of non-response.
• Scar remodeling specifically not improving. Vial identity is the thing to confirm. The anti-scarring effect runs through full-length TB-4, not the TB-500 fragment⁷; a fragment labeled as full-length will not deliver it.

Safety & Considerations

• Active cancer or malignancy within two years. Both peptides promote new blood-vessel formation, which could theoretically support an existing tumor’s blood supply. A hard contraindication during active treatment and a caution within two years of remission.
• Pregnancy or breastfeeding. No safety data for either peptide.
• Proliferative retinopathy. New blood-vessel formation may worsen the pathology.
• Recent or planned surgery. Wait until the initial clotting window has settled unless a clinician directs otherwise.
• Therapeutic anticoagulation, active autoimmune disease, or concurrent corticosteroids. Use only with medical supervision — steroids oppose the repair mechanisms these peptides drive, and TB-500 shifts immune-cell behavior in ways that can interact with autoimmune conditions.

Conventional alternatives include physical therapy, NSAIDs, and corticosteroid injections. They have different mechanisms and evidence bases; peptide protocols should not be framed as substitutes for indicated clinical care.

Regulatory & Legal Status

Neither BPC-157 nor TB-500 is FDA approved for any use, and neither is an approved injury therapy. Regulatory status does not establish either safety or therapeutic failure.

FDA compounding status. In late 2023, the FDA placed both peptides on its Category 2 bulk drug substances list. In April 2026, it removed them after the original nominations were withdrawn. Both were then scheduled for Pharmacy Compounding Advisory Committee review in July 2026. Because this access status is changing, verify the current position independently.

WADA (sport) status. Both are prohibited at all times, in and out of competition. BPC-157 is classified under S0 (non-approved substances); TB-500 falls under S2 (peptide hormones and growth factors). Metabolites of both are detectable on testing, so the stack is not usable for any drug-tested athlete.

What Evidence Exists

• BPC-157 — A 2025 systematic review covers 36 studies — 35 preclinical, 1 clinical with 12 patients³. Mechanism (angiogenesis, eNOS, FAK-paxillin) is well characterized; a hamstring-tendon Phase 2 RCT is recruiting. Clean early-phase safety; no completed modern RCT.
• TB-500 / TB-4 — Full-length TB-4 has substantial human trial data (corneal-healing Phase 2/3, plus cardiac and wound programs) with clean Phase 1 safety⁴. That data is for the full-length protein; it does not transfer to the TB-500 fragment, so verify vial identity.
• The combination — No human RCT. One rat model showed combined BPC-157 + TB-4 restored function earlier than either alone⁸. Synergy is inferred from the two mechanisms, not demonstrated in people.

FAQ

Related Topics

• BPC-157 + TB-500 Calculator — Reconstitution and per-dose math for both vials
• Wolverine Stack Guide — The narrative injury-recovery walkthrough and weekly timeline
• Injury Recovery Peptide Protocol — Five-compound framework adding NAD+, GHK-Cu, and KPV
• BPC-157 Guide — Standalone dosing, oral vs injectable, pharmacokinetics
• TB-500 / TB-4 Guide — Fragment vs full-length, certificate-of-analysis verification
• NAD+ Guide — Cellular energy support for stalled healing
• KLOW Dosage Calculator — Four-peptide blend that includes BPC-157 and TB-4 for skin and tissue repair
• Peptide Calculator — General-purpose reconstitution and dosing calculator
• Where to Inject Peptides — Near-injury vs systemic injection routing

References

¹ BPC-157 angiogenic signaling — VEGFR2–Akt–eNOS activation, nitric oxide bioavailability, endothelial sprouting, anti-cytokine modulation: PMC8275860

² TB-500 / TB-4 G-actin sequestration — actin-monomer binding maintains the reserve pool repair cells draw on for migration; mass-action pharmacodynamics favor bolus dosing: PubMed 12581423

³ BPC-157 systematic review — 36 studies (35 preclinical, 1 clinical with 12 patients); VEGF upregulation, eNOS activation, FAK-paxillin cascade. Vasireddi N et al. "Emerging Use of BPC-157 in Orthopaedic Sports Medicine." HSS J. 2025. PMC12313605

⁴ TB-4 Phase 1 safety — 84 healthy volunteers tolerated recombinant thymosin beta-4 up to 25 μg/kg daily for 10 days with no serious adverse events. Wang D et al. Ann Transl Med. 2021;9(15):1232. PMC8419156

⁵ TB-4 local-versus-systemic tissue concentration — free systemic TB-4 at a matched total dose produced no functional improvement versus a locally-targeted formulation; systemic dilution dropped tissue concentration below threshold: PMC5396927

⁶ BPC-157 tendon outgrowth — FAK-paxillin signaling promotes repair-cell outgrowth and migration. Chang et al. J Appl Physiol. 2011. PubMed 21030672

⁷ TB-4 / TB-500 mislabeling — documented bidirectional mislabeling between full-length TB-4 (43 aa) and the TB-500 fragment (residues 17–23) in marketed products. Esposito M et al. Drug Test Anal 2012. PubMed 22962027

⁸ Combined BPC-157 + TB-4 — combined administration restored contractile function earlier than either compound alone. Rahman OF et al. "Therapeutic Peptides in Orthopaedics." J Am Acad Orthop Surg Glob Res Rev. 2026;10(1). PMC12753158

⁹ KPV NF-κB inhibition — blocks nuclear translocation of NF-κB, suppresses inflammatory transcription while preserving normal immune signaling: PubMed 18061177

¹⁰ Collagen supplementation — systematic review of collagen peptide effects on synthesis and recovery; pre-exercise timing. Kirmani BH et al. Amino Acids. 2021. PMC8521576

¹¹ BPC-157 and tumor risk — narrative review of regeneration versus cancer risk; preclinical data suggests anti-tumorigenic properties in some contexts. McGuire FP et al. "Regeneration or Risk?" Curr Rev Musculoskelet Med. 2025;18(12):611–619. PMC12446177

This content is for educational purposes only. BPC-157 and TB-500 are not FDA-approved injury therapies. No human RCT exists for the combination — every protocol here is practitioner-derived, based on each compound’s mechanism and clinical observation. Consult a physician before beginning any peptide protocol, particularly with active cancer, autoimmune conditions, or medications affecting immune function or coagulation.